Bio

Bio


Dr. Sadat-Hossieny received her MD from The George Washington University in Washington, DC. She is a native of Ohio and completed her neurology residency at The Ohio State University Wexner Medical Center. She then moved to the San Francisco Bay Area for her Epilepsy Fellowship at Stanford University in 2018. She is currently working as a Clinical Instructor at Stanford University, and is devoting fifty percent of her time to research with Dr. Kimford Meador on cognition in epilepsy, with a focus on women with epilepsy and their children. Her interests lie in using the most up to date medications and technologies to provide optimal medical care to patients.

Academic Appointments


Administrative Appointments


  • Clinical Instructor, Stanford University Hospitals & Clinics (2019 - Present)

Professional Education


  • M.D., The George Washington University School of Medicine (2013)
  • Neurology Residency, The Ohio State University Wexner Medical Center (2017)
  • Epilepsy Fellowship, Stanford University Hospitals & Clinics (2019)

Publications

All Publications


  • Plateau waves of intracranial pressure mimicking seizure in a patient with fungal meningitis Wu, T., Sadat-Hossieny, Z., Gold, C. LIPPINCOTT WILLIAMS & WILKINS. 2019
  • Role of Cerebrospinal Fluid Protein and Laboratory Testing in Guillain Barre Syndrome Saba, K., Sadat-Hossieny, Z., Arnold, W., Elsheikh, B., Kline, D., Stino, A. LIPPINCOTT WILLIAMS & WILKINS. 2019
  • Pharmacological Agents in Aneurysmal Subarachnoid Hemorrhage: Successes and Failures CLINICAL NEUROPHARMACOLOGY Behrouz, R., Sadat-Hosseiny, Z. 2015; 38 (3): 104?8

    Abstract

    Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating condition with high mortality. Proper management of this complex disease requires early surgical intervention followed by medical therapy. Pharmacological agents that unequivocally improve outcomes in aSAH are scarce.The authors performed an exhaustive query of several databases including MEDLINE, the CENTRAL Register of Controlled Trials, and the Cochrane Database of Systematic Reviews for specific evidence on key medications that have been used in the treatment of aSAH.The bulk of the data available pertained to the following medications: calcium channel blockers, magnesium, statins, antifibrinolytics, aspirin, glucocorticoids, clazosentan, and tirilazad. Except for calcium channel blockers, the authors could not find any hard evidence that any of these agents affected outcome to a tangible degree. Aspirin may have some promise in prevention of aneurysm rupture and incidence of aSAH, but more substantive data are needed to conclusively corroborate this.Investigational efforts to attain outcome-modifying agents have had dubious results, but the inquest for discovery should not discontinue.

    View details for DOI 10.1097/WNF.0000000000000085

    View details for Web of Science ID 000354655200004

    View details for PubMedID 25970278

Footer Links:

Stanford Medicine Resources: